AstraZeneca

Qiagen, AstraZeneca collaborate for lung cancer patients

Monday, July 28, 2014 02:53 PM

Qiagen, a Netherlands-based holding company, has announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AZ's targeted therapy for non-small cell lung cancer (NSCLC).

More... »

WIRB Copernicus Group

Seven pharma companies offer deprioritized compounds for re-purposing

Wednesday, July 23, 2014 10:15 AM

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.

More... »

CRF Health eCOA webinar series

AstraZeneca reveals designs for new U.K. global R&D center, corporate headquarters

Monday, July 21, 2014 03:03 PM

AstraZeneca revealed its proposed designs for its new global R&D center and corporate headquarters in Cambridge, U.K. The facility, which will be located on the Cambridge Biomedical Campus (CBC), includes the global center, an R&D enabling building and an energy center.

More... »

Covance adds two to clinical development services leadership team

Monday, July 14, 2014 01:04 PM

Covance has announced two key additions to its clinical development services scientific leadership team with the appointments of Robert Wasserman, M.D., as vice president and global therapeutic area head, oncology, and Rogelio Mosqueda-Garcia, M.D., Ph.D., as global vice president, early clinical services within medical and scientific affairs. Both are based in Princeton, N.J.

More... »

AstraZeneca, Max Planck Institute to create satellite chemistry unit

Wednesday, July 9, 2014 12:03 PM

The Max Planck Institute of Molecular Physiology (MPI), Germany, will establish a satellite unit in cardiovascular and metabolic disease (CVMD) with AstraZeneca's CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.

More... »

Medical Research Council launches U.K. Dementias Research Platform

Thursday, June 19, 2014 01:39 PM

The Medical Research Council (MRC) has launched the U.K. Dementias Research Platform (UKDP), a $27.2 million public-private partnership set up to speed up research into dementias. The collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

More... »

Exco InTouch, AstraZeneca mHealth collaboration produces Me&MyCOPD

Thursday, June 19, 2014 01:38 PM

Exco InTouch, a provider of digital patient engagement and data capture solutions for healthcare providers, said its collaboration with AstraZeneca has led to the development of an mHealth program Me&MyCOPD ,which improves condition management for patients suffering from chronic obstructive pulmonary disease (COPD), as well as for their caregivers and healthcare providers.

More... »

ADDC, AstraZeneca partner for drug development in academic research

Wednesday, June 18, 2014 12:54 PM

The Academic Drug Discovery Consortium (ADDC) has formed a collaboration with AstraZenecaaimed at facilitating efforts by researchers from academia and institutions toward the discovery of novel compounds with potential pharmaceutical application. More specifically, the goal of this partnership is to provide ADDC members with access to a high-quality compound library, while allowing AZ the opportunity to collaborate with academic researchers to identify novel disease targets and drugs across a wide range of therapy areas.

More... »

Amgen joins NCI to accelerate development of personalized cancer treatments

Tuesday, June 17, 2014 10:26 AM

Amgen will collaborate with the National Cancer Institute (NCI), part of the NIH, and other public and private sector partners, on the Lung Master Protocol (Lung-MAP), a new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.

More... »

AstraZeneca in-licenses Synairgen's SNG001 for asthma in $232M deal

Thursday, June 12, 2014 01:38 PM

AstraZeneca has inked a global license agreement with Synairgen, a U.K. company specializing in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. SNG001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs